Using Male Peer Networks to Increase HIV Self-Testing and PrEP Use Among Men in Eastern Zimbabwe
Led by University of Stellenbosch · Updated on 2025-05-04
3591
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are exploring new ways to engage men in Sub-Saharan Africa with HIV testing, treatment, and prevention services to help reduce HIV infections. Men often have lower participation in HIV prevention, increasing their risk and contributing to new infections in women. This study focuses on how distributing HIV self-testing kits through male peer networks, supported by phone assistance and better risk awareness, affects the use of HIV prevention medicine called PrEP among men in Eastern Zimbabwe.
The study uses a cluster-randomized design with 44 community clusters, each with about 81 men, divided into two groups one receiving peer-distributed HIV self-testing kits and the other receiving kits from community health workers as usual care. In the peer distribution group, initial distributors get kits for themselves and peers, who can also become distributors, spreading the testing through social networks. Support is provided via a toll-free helpline and SMS risk assessments to encourage quick clinic visits for PrEP. Distributors and participants receive small payments for their involvement.
Participants will be followed for six months to track PrEP initiation, clinic attendance, HIV testing, and treatment starts. The study team collects data through calls, referrals, and clinic records, including blood tests to confirm medication adherence. They will also evaluate how well the program is implemented and its effects on HIV prevention. The total involvement includes enrolling distributors, distributing kits, follow-up calls, clinic visits, and monthly contact for support and adherence checks.
CONDITIONS
Brief Title
Harnessing Male Peer Networks to Enhance Engagement With HIV Prevention
Research Team
C
Constance Nyamukapa, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Biomedical Research and Training Institute, Zimbabwe
Collaborating Sponsor
Who Can Participate
Age: 18Years +
MALE
Healthy Volunteers
Eligibility Criteria
You may qualify if you...
Resident in study site
You will not qualify if you...
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening and enrollment visit (in-person)
Outpatient Treatment
Duration - Up to 6 months
Participants identified as distributors receive HIV self-test kits for personal use and to distribute within their community. They are advised on the correct use of the kits, post-test confirmatory testing, and HIV prevention methods including PrEP.
Regular contacts via helpline and community facility visits to collect and distribute HIV self-test kits
Outpatient Treatment
Duration - Up to 6 months
Recipients of HIV self-test kits are contacted by the helpdesk to confirm receipt and use of kits, and encouraged to attend healthcare facilities for confirmatory testing and PrEP screening.
Multiple telephone follow-ups and community facility visits as needed
Outpatient Treatment
Duration - 6 months
Participants who initiate PrEP or antiretroviral therapy (ART) are contacted monthly for six months to provide support and monitor adherence and continuation of treatment.
Monthly follow-up contacts (telephone or in-person)
Follow-up
Duration - Single visit after 6 months
At the end of the follow-up period, participants still taking PrEP or ART provide a blood sample to verify adherence through laboratory analysis.
1 visit (blood sample collection)
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Similar Trials
Continued Access Study Providing Ongoing HIV Treatment for Participants from ViiV Healthcare Parent Studies
Long-Term Follow-Up Study of HIV-Infected Individuals from HIV-NAT Trials to Evaluate Clinical Outcomes and Treatment Effects
Phase 2b Study Comparing Oral VH4524184 with Standard HIV Treatment in Adults Newly Diagnosed with HIV-1
Evaluating Treatment Strategies for Managing Virologic Failure on Tenofovir, Lamivudine, and Dolutegravir TLD in People with HIV in Sub-Saharan Africa
Pilot Study of a Peer-Driven Injection Setting Intervention to Prevent HIV, Hepatitis C, and Overdose Among People Who Inject Drugs in Baltimore
Phase 1 Study of VH4011499 Safety, Tolerability, and Pharmacokinetics
with Single and Multiple Doses in Adults Without HIV
Safety and Effectiveness of JL18008 Injections Added to Standard HIV Therapy
in Adults with HIV Who Have Low Immune Response
A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Phase 12 Study to Assess Safety and Effects of Cabotegravir in Newborns Exposed to HIV-1
Phase III Study Comparing Cabotegravir and Rilpivirine Ultra Long-Acting or Long-Acting Treatments in Adolescents and Adults With Suppressed HIV
Phase 1 Randomized, Double-Blind, Placebo-Controlled Study of Single-Dose VH4367310 in Healthy Adults Aged 18 to 55 Years
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
IMPERATIVE: Harnessing male peer networks to enhance engagement with HIV prevention: A large-scale cluster randomised trial to increase HIV self-testing and PrEP uptake among men in Eastern Zimbabwe.